PharmaResearch Statistics
Total Valuation
PharmaResearch has a market cap or net worth of KRW 2.99 trillion. The enterprise value is 2.84 trillion.
Market Cap | 2.99T |
Enterprise Value | 2.84T |
Important Dates
The last earnings date was Friday, February 7, 2025.
Earnings Date | Feb 7, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
PharmaResearch has 10.39 million shares outstanding. The number of shares has increased by 1.41% in one year.
Current Share Class | n/a |
Shares Outstanding | 10.39M |
Shares Change (YoY) | +1.41% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 38.61% |
Owned by Institutions (%) | 18.43% |
Float | 5.20M |
Valuation Ratios
The trailing PE ratio is 35.75 and the forward PE ratio is 22.48. PharmaResearch's PEG ratio is 0.78.
PE Ratio | 35.75 |
Forward PE | 22.48 |
PS Ratio | 9.31 |
PB Ratio | 5.84 |
P/TBV Ratio | 6.25 |
P/FCF Ratio | 31.40 |
P/OCF Ratio | n/a |
PEG Ratio | 0.78 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.61, with an EV/FCF ratio of 29.81.
EV / Earnings | 32.01 |
EV / Sales | 8.96 |
EV / EBITDA | 21.61 |
EV / EBIT | 23.94 |
EV / FCF | 29.81 |
Financial Position
The company has a current ratio of 4.05, with a Debt / Equity ratio of 0.06.
Current Ratio | 4.05 |
Quick Ratio | 3.07 |
Debt / Equity | 0.06 |
Debt / EBITDA | 0.25 |
Debt / FCF | 0.33 |
Interest Coverage | 137.08 |
Financial Efficiency
Return on equity (ROE) is 17.83% and return on invested capital (ROIC) is 13.17%.
Return on Equity (ROE) | 17.83% |
Return on Assets (ROA) | 11.98% |
Return on Invested Capital (ROIC) | 13.17% |
Return on Capital Employed (ROCE) | 20.22% |
Revenue Per Employee | 775.05M |
Profits Per Employee | 217.01M |
Employee Count | 409 |
Asset Turnover | 0.54 |
Inventory Turnover | 1.79 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +216.94% in the last 52 weeks. The beta is 0.52, so PharmaResearch's price volatility has been lower than the market average.
Beta (5Y) | 0.52 |
52-Week Price Change | +216.94% |
50-Day Moving Average | 256,170.00 |
200-Day Moving Average | 193,150.00 |
Relative Strength Index (RSI) | 61.16 |
Average Volume (20 Days) | 116,051 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaResearch had revenue of KRW 317.00 billion and earned 88.76 billion in profits. Earnings per share was 8,057.05.
Revenue | 317.00B |
Gross Profit | 224.99B |
Operating Income | 112.73B |
Pretax Income | 112.55B |
Net Income | 88.76B |
EBITDA | 125.54B |
EBIT | 112.73B |
Earnings Per Share (EPS) | 8,057.05 |
Balance Sheet
The company has 216.41 billion in cash and 31.90 billion in debt, giving a net cash position of 184.51 billion or 17,758.78 per share.
Cash & Cash Equivalents | 216.41B |
Total Debt | 31.90B |
Net Cash | 184.51B |
Net Cash Per Share | 17,758.78 |
Equity (Book Value) | 543.03B |
Book Value Per Share | 49,305.53 |
Working Capital | 254.31B |
Cash Flow
In the last 12 months, operating cash flow was 122.27 billion and capital expenditures -26.99 billion, giving a free cash flow of 95.28 billion.
Operating Cash Flow | 122.27B |
Capital Expenditures | -26.99B |
Free Cash Flow | 95.28B |
FCF Per Share | 9,170.86 |
Margins
Gross margin is 70.97%, with operating and profit margins of 35.56% and 28.00%.
Gross Margin | 70.97% |
Operating Margin | 35.56% |
Pretax Margin | 35.51% |
Profit Margin | 28.00% |
EBITDA Margin | 39.60% |
EBIT Margin | 35.56% |
FCF Margin | 30.06% |
Dividends & Yields
This stock pays an annual dividend of 950.00, which amounts to a dividend yield of 0.33%.
Dividend Per Share | 950.00 |
Dividend Yield | 0.33% |
Dividend Growth (YoY) | 43.94% |
Years of Dividend Growth | 4 |
Payout Ratio | 11.80% |
Buyback Yield | -1.41% |
Shareholder Yield | -1.08% |
Earnings Yield | 2.97% |
FCF Yield | 3.18% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
PharmaResearch has an Altman Z-Score of 10.31.
Altman Z-Score | 10.31 |
Piotroski F-Score | n/a |